Rethinking AD — Beyond Inflammation
Atopic dermatitis remains common and stubborn, especially in pediatric patients, because inflammation is only one part of a self‑reinforcing loop that includes microbiome disruption, neuroimmune and behavioral drivers, and systemic influences like the skin‑gut axis. Patients’ rising steroid‑hesitancy and interest in integrative options mean we should be open to safe, multi‑target strategies that address barrier, microbes, itch behavior, and inflammation together. Botanical agents such as zabalafin (Alphyn) — reported to combine anti‑inflammatory, antipruritic, antimicrobial, and anti‑xerotic effects — offer a promising, patient‑friendly approach, though robust clinical data are still needed.
Want the clinical rationale, mechanism summary, and how this might change your treatment conversations? Read the full article for the evidence and practical next steps.
J Drugs Dermatol. 2025;24(10). doi:10.36849/JDD.9215
Blog write-up assisted by AI
